These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37201044)

  • 1. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.
    Takahashi S; Ouchi K; Sakamoto Y; Mori T; Shimodaira H; Takahashi M; Ohori H; Kudo C; Takahashi Y; Imai H; Akiyama S; Takahashi M; Suto T; Murakawa Y; Oishi T; Isobe H; Okada Y; Kawai S; Yoshioka T; Sato T; Shindo Y; Sugiyama S; Komine K; Chiba N; Okita A; Yamaguchi T; Ishioka C
    J Gastrointest Oncol; 2023 Apr; 14(2):676-691. PubMed ID: 37201044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
    Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
    JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
    Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
    Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial.
    Ouchi K; Takahashi S; Sasaki K; Yoshida Y; Taniguchi S; Kasahara Y; Komine K; Imai H; Saijo K; Shirota H; Takahashi M; Ishioka C
    Int J Colorectal Dis; 2024 Jun; 39(1):89. PubMed ID: 38862615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16.
    Yasui H; Okita Y; Nakamura M; Sagawa T; Watanabe T; Kataoka K; Manaka D; Shiraishi K; Akazawa N; Okuno T; Shimura T; Shiozawa M; Sunakawa Y; Ota H; Kotaka M; Okuyama H; Takeuchi M; Ichikawa W; Fujii M; Tsuji A
    ESMO Open; 2023 Oct; 8(5):101636. PubMed ID: 37703596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.
    Kasper S; Meiler J; Knipp H; Höhler T; Reimer P; Steinmetz T; Berger W; Linden G; Reis H; Markus P; Paul A; Dechêne A; Schumacher B; Kostbade K; Virchow I; Ting S; Worm K; Schmid KW; Herold T; Wiesweg M; Schuler M; Trarbach T
    Clin Colorectal Cancer; 2020 Dec; 19(4):236-247.e6. PubMed ID: 32737003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
    Sastre J; García-Alfonso P; Viéitez JM; Cano MT; Rivera F; Reina-Zoilo JJ; Salud-Salvia A; Quintero G; Robles-Díaz L; Safont MJ; La Casta A; Gil S; Polo E; Asensio-Martínez E; García-Paredes B; López RL; Guillot M; Valladares-Ayerbes M; Aranda E; Díaz-Rubio E;
    ESMO Open; 2021 Apr; 6(2):100062. PubMed ID: 33711671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
    Martini G; Ciardiello D; Famiglietti V; Rossini D; Antoniotti C; Troiani T; Napolitano S; Esposito L; Latiano TP; Maiello E; Del Re M; Lonardi S; Aprile G; Santini D; Masi G; Avallone A; Normanno N; Pietrantonio F; Pinto C; Ciardiello F; Cremolini C; Martinelli E
    Cancer Med; 2023 Apr; 12(8):9392-9400. PubMed ID: 36880426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
    Boige V; Blons H; François E; Ben Abdelghani M; Phelip JM; Le Brun-Ly V; Mineur L; Galais MP; Villing AL; Hautefeuille V; Miglianico L; De La Fouchardière C; Genet D; Levasseur N; Levaché CB; Penel N; Mitry E; Jacquot S; Aparicio T; Brument E; Gourgou S; Castan F; Bouché O
    JAMA Netw Open; 2023 Sep; 6(9):e2333533. PubMed ID: 37721754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
    Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
    Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
    BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.
    Osumi H; Shinozaki E; Mashima T; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Ota Y; Nakayama I; Takahari D; Chin K; Miki Y; Yamaguchi K
    Cancer Sci; 2018 Aug; 109(8):2567-2575. PubMed ID: 29908105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
    Cheng AL; Cornelio G; Shen L; Price T; Yang TS; Chung IJ; Dai GH; Lin JK; Sharma A; Yeh KH; Ma B; Zaatar A; Guan Z; Masood N; Srimuninnimit V; Yau T; Gibbs P; Wang X; Doval DC; Oh ST; Shim BY; Gorospe C; Wang HM; Sirachainan E; Hill A; Suh KW; Beier F; Chatterjee S; Lim R
    Clin Colorectal Cancer; 2017 Jun; 16(2):e73-e88. PubMed ID: 27780749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin Toxicity as Predictor of Survival in Refractory Patients with
    Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Normanno N; Avallone A; Latiano T; Maiello E; Pietrantonio F; Cremolini C; Santabarbara G; Pinto C; Troiani T; Martinelli E; Ciardiello F; Martini G
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.
    Price T; Shen L; Ma B; Esser R; Chen W; Gibbs P; Lim R; Cheng AL
    Asia Pac J Clin Oncol; 2019 Aug; 15(4):225-230. PubMed ID: 31090260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer.
    Zekri J; Baghdadi MA; Ibrahim RB; Meliti A; Sobahy TM
    Ecancermedicalscience; 2022; 16():1490. PubMed ID: 36819803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.